Pharmacotherapy for Obesity Management

This set of flashcards focuses on key terms and definitions related to pharmacotherapy for obesity management, aiding in understanding crucial concepts for the upcoming exam.

Pharmacotherapy

An effective and safe approach to treating obesity and assisting in health behavior changes.

Body Mass Index (BMI)

A measure that defines obesity and overweight, although it does not reflect body composition adequately.

Liraglutide (Saxenda®)

One of the six medications approved for long-term obesity management in Canada.

Tirzepatide (Zepbound®)

A medication indicated for long-term obesity management and is a dual GIP/GLP-1 receptor agonist.

Naltrexone/Bupropion (Contrave®)

A combination medication approved for obesity management, influencing satiety and cravings.

Setmelanotide (Imcivree®)

A medication used for weight management in specific genetic conditions causing obesity.

Waist Circumference

A measure of central adiposity used alongside ethnicity-specific BMI thresholds to guide treatment decisions.

Adiposity-related complications

Health issues associated with excess body fat that obesity treatment aims to address.

Cardiovascular risk

A potential consideration in obesity management, influenced by pharmacotherapy.

Quality of Life (QoL)

An important outcome in obesity management, improved through effective weight management strategies.

Weight Regain

A common occurrence after stopping obesity pharmacotherapy, highlighting the need for long-term management strategies.